BRISBANE, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class 1 therapeutics that combine both targeted ...

Amezalpat, Tempest's lead candidate, has received both Orphan Drug and Fast Track designations from the FDA. TPST-1495, a dual EP2/EP4 antagonist, is also advancing toward a Phase 2 trial in ...